Welcome to our dedicated page for Lensar news (Ticker: LNSR), a resource for investors and traders seeking the latest updates and insights on Lensar stock.
LENSAR, Inc. (Nasdaq: LNSR) is a commercial-stage medical device and global medical technology company focused on advanced laser systems for the treatment of cataracts and the management of astigmatism. News about LENSAR often centers on its ALLY Robotic Cataract Laser System, financial performance, and the company’s pending acquisition by Alcon Research, LLC.
Regular earnings releases provide updates on quarterly revenue, procedure volumes performed on LENSAR’s installed base of laser systems, and the mix between system sales and recurring revenue from procedures, leases, and service. These reports also discuss non-GAAP metrics such as EBITDA and Adjusted EBITDA, along with commentary on operational initiatives and utilization of the ALLY system in the United States and abroad.
Another recurring news theme is corporate and capital markets activity. LENSAR has announced a definitive merger agreement under which Alcon intends to acquire the company, including the ALLY Robotic Cataract Laser Treatment System, Streamline software technology, and the LENSAR legacy laser system. Subsequent updates describe stockholder approval of the merger proposal and ongoing regulatory review, including interactions with the U.S. Federal Trade Commission.
LENSAR also issues announcements related to equity compensation, such as inducement grants of restricted stock units and stock options to newly hired non-executive employees under its Employment Inducement Incentive Award Plan. These items provide insight into hiring and compensation practices. Investors and observers who follow LNSR news can use this page to review earnings releases, merger-related developments, and governance and compensation updates in one place.
LENSAR, Inc. (Nasdaq: LNSR), a global medical technology company specializing in advanced laser solutions for cataract treatment, has announced the release of its second quarter 2024 financial results. The results will be made public before the market opens on Thursday, August 8, 2024. Following this, LENSAR's management team will host a conference call and webcast at 8:30 am ET on the same day to discuss the financial outcomes and recent company highlights.
Interested parties can join the call by dialing (800) 274 8461 (Domestic) or (203) 518 9848 (International) using the conference ID: LENSAR. A live webcast will also be available in the Investors section of LENSAR's website at www.lensar.com. An archived version of the call will be accessible on the website after the live event.
LENSAR announced that its board of directors granted stock options to three new non-executive employees. A total of 1,200 shares are available for purchase under these options, which were issued as a hiring inducement. The grant date was July 2, 2024, and the exercise price is set at $4.31 per share, matching the closing stock price on that date. Options will vest 25% after one year from July 1, 2024, with the remaining shares vesting in equal monthly installments over the next three years, contingent on continued employment. Each stock option carries a 10-year term and follows LENSAR's 2024 Employment Inducement Incentive Award Plan.
LENSAR announced the inducement grants under Nasdaq Listing Rule 5635(c)(4), awarding stock options to three newly-hired non-executive employees. These options, totaling 2,150 shares, were granted as of June 3, 2024, with an exercise price of $4.64 per share, matching the closing price on the grant date. The vesting schedule includes 25% after one year and the remaining shares in equal monthly installments over the next three years. Each option has a 10-year term and is part of LENSAR's 2024 Employment Inducement Incentive Award Plan, subject to a stock option agreement.
LENSAR (Nasdaq: LNSR), a global leader in femtosecond laser solutions for cataract treatment, announced that CEO Nick Curtis will participate in a Fireside Chat at the 2024 Leerink Partners Healthcare Crossroads Conference. This event will take place on May 29, 2024, at 1:40 p.m. CT in Austin, TX.
The live and archived webcast will be accessible via the Investors section of LENSAR's website and will be available for one month after the presentation.
LENSAR, Inc. (Nasdaq: LNSR) reported a 28% increase in total revenue and a 25% increase in procedure volume for the first quarter of 2024 compared to the same period in 2023. The ALLY® Adaptive Cataract Treatment System installed base grew to 65 systems. The company achieved 20%+ revenue growth, with total revenue reaching $10.6 million, up 28% year-over-year. U.S. procedure volume increased by 23% and worldwide volume by 25% in Q1 2024. LENSAR's U.S. procedure share grew by 1.5% in Q1 2024 and has seen a 4.3% growth since the launch of ALLY.
LENSAR, Inc. (Nasdaq: LNSR) will report its first quarter 2024 financial results on Thursday, May 9, 2024. The global medical technology company specializing in femtosecond laser solutions for cataract treatment will host a conference call and webcast to discuss the results and recent corporate highlights.
LENSAR, Inc. (Nasdaq: LNSR) granted two newly-hired non-executive employees stock options to purchase 875 shares of common stock. The options were granted as of May 1, 2024, with an exercise price of $3.07 per share. They vest over time based on continued service. The options are in line with Nasdaq Listing Rule 5635(c)(4) and are subject to the company's 2024 Employment Inducement Incentive Award Plan.
Summary not available.
Summary not available.
Summary not available.